Cagrilintide
Also known as: AM833
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Overview
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.
Key benefits
- FDA development candidate with extensive Phase 3 data
- Superior weight loss in combination with semaglutide (22.7%)
- Once-weekly convenience
- 2.2% HbA1c reduction with CagriSema
Mechanism of action
Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.
Molecular data
- Type
- Amylin receptor agonist
- Half-life
- ~7 days (159-195 hours)
Sequence
37-amino acid peptide
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Metabolic
Appetite Control
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 2.4mg | Once weekly | — |
| — | 2.4mg + semaglutide 2.4mg | Once weekly | — |
| — | 2.4mg weekly | Once weekly | — |
| — | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg | Weekly increases over 16 weeks | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
- Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
- Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Contraindications
- Not recommended in pregnancy or breastfeeding
- Not yet commercially available (FDA approval expected Q1 2026)
Monitoring
- No clinically significant QT prolongation observed
- Monitor for fibril formation in reconstituted solution (must remain clear)
References
Primary literature and clinical-trial data informing this entry.